ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Historical Holders from Q1 2018 to Q3 2025

Symbol
RCKT on Nasdaq
Type / Class
Equity / Common Stock, $0.01 par value per share
Shares outstanding
107M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
96.6M
Holdings value
$315M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
170
Number of buys
88
Number of sells
-111
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAVERICK CAPITAL LTD 7.8% +52% $26.4M $8.9M 8.36M +50.8% Maverick Capital, Ltd. 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 0.9% -82.9% $7.9M -$48.3M 1M -86% Wellington Management Group LLP 30 May 2025

Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 96.6M $315M +$10.6M $3.26 170
2025 Q2 95M $233M -$148M $2.45 194
2025 Q1 108M $722M -$52.7M $6.67 233
2024 Q4 110M $1.38B +$162M $12.57 222
2024 Q3 92.7M $1.71B +$19M $18.47 189
2024 Q2 91.2M $1.96B -$33.5M $21.53 176
2024 Q1 92M $2.48B +$111M $26.94 183
2023 Q4 89M $2.67B -$7.08M $29.97 192
2023 Q3 89.4M $1.83B +$255M $20.49 174
2023 Q2 76.3M $1.52B -$31.9M $19.87 162
2023 Q1 78.3M $1.34B +$44.8M $17.13 161
2022 Q4 75.9M $1.49B +$148M $19.57 167
2022 Q3 69.1M $1.1B +$66M $15.96 159
2022 Q2 64.5M $887M +$4.04M $13.76 141
2022 Q1 64.3M $1.02B +$10.5M $15.86 142
2021 Q4 63.1M $1.38B +$9.05M $21.83 141
2021 Q3 62M $1.85B -$24.6M $29.89 142
2021 Q2 61.8M $2.74B -$11M $44.29 144
2021 Q1 62M $2.75B -$22.9M $44.37 169
2020 Q4 62M $3.4B +$432M $54.84 172
2020 Q3 55.2M $1.26B +$20M $22.86 124
2020 Q2 53.3M $1.12B +$14.5M $20.93 113
2020 Q1 53.3M $744M +$12.2M $13.95 102
2019 Q4 51.7M $1.18B +$87.8M $22.76 116
2019 Q3 47.7M $555M -$32.6M $11.65 91
2019 Q2 49.1M $736M +$92.6M $15.00 96
2019 Q1 42.9M $751M +$16.3M $17.54 80
2018 Q4 42.1M $622M +$68.8M $14.82 86
2018 Q3 36.8M $906M +$70.6M $24.62 82
2018 Q2 31.1M $605M +$63.9M $19.63 75
2018 Q1 28M $502M +$502M $18.75 55